These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1275 related items for PubMed ID: 23602654

  • 1. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR, Choe YJ, Go UY, Kim YI, Lee JK.
    Vaccine; 2013 May 31; 31(24):2661-6. PubMed ID: 23602654
    [Abstract] [Full Text] [Related]

  • 2. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [Abstract] [Full Text] [Related]

  • 3. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ, Zhang B, Yan R, Li Q, Fu J, Tang XW, Zhou Y, Deng X, Xie SY.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug 10; 37(8):1121-6. PubMed ID: 27539345
    [Abstract] [Full Text] [Related]

  • 4. A benefit-cost analysis of two-dose measles immunization in Canada.
    Pelletier L, Chung P, Duclos P, Manga P, Scott J.
    Vaccine; 1998 Aug 10; 16(9-10):989-96. PubMed ID: 9682349
    [Abstract] [Full Text] [Related]

  • 5. Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001.
    Choe YJ, Eom HE, Cho SI.
    J Med Virol; 2017 Sep 10; 89(9):1528-1531. PubMed ID: 28303592
    [Abstract] [Full Text] [Related]

  • 6. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.
    N Engl J Med; 1994 Nov 24; 331(21):1397-402. PubMed ID: 7969278
    [Abstract] [Full Text] [Related]

  • 7. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC, Burgess MA, O'Brien ED.
    Commun Dis Intell; 1998 Aug 06; 22(8):159. PubMed ID: 9735551
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Benefits, risks and costs of immunization for measles, mumps and rubella.
    White CC, Koplan JP, Orenstein WA.
    Am J Public Health; 1985 Jul 06; 75(7):739-44. PubMed ID: 3923849
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ, Robertson PW, Whybin LR.
    Med J Aust; 1994 Apr 18; 160(8):478-82. PubMed ID: 8170422
    [Abstract] [Full Text] [Related]

  • 11. MMR vaccination and disease elimination: the Finnish experience.
    Davidkin I, Kontio M, Paunio M, Peltola H.
    Expert Rev Vaccines; 2010 Sep 18; 9(9):1045-53. PubMed ID: 20822347
    [Abstract] [Full Text] [Related]

  • 12. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep 04; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract] [Full Text] [Related]

  • 13. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.
    Vaccine; 2014 Feb 26; 32(10):1147-52. PubMed ID: 24440207
    [Abstract] [Full Text] [Related]

  • 14. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530
    [Abstract] [Full Text] [Related]

  • 15. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ, Li Q, Yan R, Zhou Y, Tang XW, Deng X, Xie SY, Chen ZP.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr 06; 51(4):336-340. PubMed ID: 28395468
    [Abstract] [Full Text] [Related]

  • 16. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P, Amstad H, Grize L, Gassner M, Takken-Sahli K, Bourquin C, Braun-Fahrländer C.
    Praxis (Bern 1994); 1999 Jun 10; 88(24):1069-77. PubMed ID: 10420798
    [Abstract] [Full Text] [Related]

  • 17. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Jun 14; 62(RR-04):1-34. PubMed ID: 23760231
    [Abstract] [Full Text] [Related]

  • 18. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P.
    Ann Ig; 1998 Jun 14; 10(1):19-24. PubMed ID: 9616974
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.